<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56887">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01738633</url>
  </required_header>
  <id_info>
    <org_study_id>QOLEC1 - step 2</org_study_id>
    <nct_id>NCT01738633</nct_id>
  </id_info>
  <brief_title>Quality of Life After Esophagectomy for Cancer - Step 2</brief_title>
  <official_title>Quality of Life After Esophagectomy for Cancer - Step 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Berlucchi Foundation, Brescia, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Oncologico Veneto I.O.V. - I.R.C.C.S.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: A recent systematic review showed that patients undergoing esophagectomy for
      cancer had scores of physical function, vitality and performance of health in general
      significantly lower than those obtained from the reference population. The analysis of the
      quality of life at six months follow-up showed that the total score and physical function
      were better before surgery and symptoms-based scales indicated that the fatigue, dyspnoea
      and diarrhea were worse six months after esophagectomy. The objective of this study is
      therefore to assess the impact of esophageal resections for cancer on the quality of life of
      patients and to improve it through simple interventions of post operative care.

      The study is divided into two steps.

      This is step 2.

      At hospital discharge, patients will be randomized into 4 groups receiving respectively:
      nutritional and respirology counseling; nutritional counseling alone; respirology counseling
      alone; standard care. All the patients fill in the questionnaires QLQ C30, OES18, INPAT32 at
      1 and 3 months after the surgical operation. Primary end-points are the items DY (dyspnoea),
      AP (appetite loss) and QL2 of QLQ C30. Secondary end point is the item EA (eating) of OES18.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>items DY (dyspnoea), AP (appetite loss) and QL2 of the QLQ C30</measure>
    <time_frame>1 month after surgical operation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>item EA (eating) of OES18</measure>
    <time_frame>1 month after surgical operation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>items DY (dyspnoea), AP (appetite loss) and QL2 of the QLQ C30</measure>
    <time_frame>3 months after surgical operation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>item EA (eating) of OES18</measure>
    <time_frame>3 months after surgical operation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>nutritional + respirology counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive both nutritional and respirology counseling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nutritional counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive nutritional counseling alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>respirology counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive respirology counseling alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will receive standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>nutritional counseling</intervention_name>
    <arm_group_label>nutritional + respirology counseling</arm_group_label>
    <arm_group_label>nutritional counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>respirology counseling</intervention_name>
    <arm_group_label>nutritional + respirology counseling</arm_group_label>
    <arm_group_label>respirology counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age above 18 years old

          -  scheduled for esophagectomy for cancer

        Exclusion Criteria:

          -  age below 18 years old

          -  incapability to autonomously fill in questionnaires

          -  primary language not italian
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlo Castoro, MD</last_name>
    <phone>+ 39 049 821 1693</phone>
    <email>carlo.castoro@unipd.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto (IOV-IRCCS)</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Castoro, MD</last_name>
      <phone>+39 049 821 1693</phone>
      <email>carlo.castoro@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Marco Scarpa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Cagol, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Alfieri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenza Caregaro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariateresa Nardi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Marchi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Vianello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleonora Pinto, Psy. D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Parotto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabetta Saraceni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabio Baratto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca M Sadeeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>October 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Quality of Life</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
